Light Chain (AL) Amyloidosis
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
150%
Monoclonal Antibody
150%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ProthenaBirtamimab
NexcellaNXC-201 CAR-T
Clinical Trials (2)
Total enrollment: 208 patients across 2 trials
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Start: Aug 2021Est. completion: Jun 2025208 patients
Phase 3Terminated
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Start: Jun 2024Est. completion: Jan 2039
Phase 1/2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 208 patients
Cell Therapy is the dominant modality (50% of programs)
2 companies competing in this space